Abstract
There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Current Drug Targets
Title: How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Volume: 12 Issue: 10
Author(s): Raja Affendi Raja Ali and Laurence John Egan
Affiliation:
Keywords: Inflammatory bowel disease, Ulcerative Colitis, Surveillance colonoscopy, dysplasia, colorectal cancer, colectomy, Crohn's disease, NSAIDs, Ursodeoxycholic acid, Chromoendoscopy, Narrow-Band Imging, Confocal Endomicroscopy, DALMs
Abstract: There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are ‘at-risk’ of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.
Export Options
About this article
Cite this article as:
Affendi Raja Ali Raja and John Egan Laurence, How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818270
DOI https://dx.doi.org/10.2174/138945011796818270 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
QSAR Study on MHC Class I A Alleles Based on the Novel Parameters of Amino Acids
Protein & Peptide Letters MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease
Current Drug Targets The Cytotoxic and Mechanistic Effects of Aaptamine on Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Trastuzumab Resistance in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Editorial
Current Medical Imaging Synthesis of Asymmetric 1-Thiocarbamoyl Pyrazoles as Potent Anti- Colon Cancer, Antioxidant and Anti-Inflammatory Agent
Anti-Cancer Agents in Medicinal Chemistry NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect
Current Medicinal Chemistry Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
Current Cancer Drug Targets Editorial [Hot Topic (2): Current Advances in Cancer Prevention and Treatment by Natural Products (Guest Editor: Anupam Bishayee, M.Pharm., Ph.D.)]
Current Pharmaceutical Biotechnology Kefir: A Synbiotic with Approved Anticarcinogenic Properties
Current Bioactive Compounds Radiolabeled Nucleosides for Predicting and Monitoring the Cancer Therapeutic Efficacy of Chemodrugs
Current Medicinal Chemistry Recent Advances in Predicting Functional Impact of Single Amino Acid Polymorphisms: A Review of Useful Features, Computational Methods and Available Tools
Current Bioinformatics Modelling DNA Repair Pathways: Recent Advances and Future Directions
Current Pharmaceutical Design